Cepharanthine (千金藤素) - Investigational Therapy for Parkinson's Disease

Cepharanthine (千金藤素) — Investigational Therapy for Parkinson's Disease

Overview

Cepharanthine (also known as 千金藤素) is a natural bisbenzylisoquinoline alkaloid extracted from the plant Stephania cepharantha Hayata, used traditionally in Chinese medicine for over 70 years. It is being investigated as a potential disease-modifying treatment for Parkinson's disease (PD) due to its multi-target neuroprotective properties that address multiple pathogenic pathways simultaneously["@cepharanthine2015"][@cepharanthine2020].

Compound Information

| Property | Value |
|----------|-------|
| Chemical Name | (1R,2S,3R,4S,6R,7S,8R,13R,14R,15S,16S)-1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17-Octadecahydro-1,6-epoxy-4,15-dihydroxy-5,11-dimethyl-8-(1-methylethenyl)-7,13-epoxy-15H-cyclopenta[a]azulene-3-carboxylic acid |
| Molecular Formula | C₃₇H₃₈N₂O₆ |
| Molecular Weight | 606.7 g/mol |
| Class | Bisbenzylisoquinoline alkaloid |
| Source | Stephania cepharantha (Japanese: Kikyo, Chinese: Jin Qian Teng) |
| Traditional Uses | Anti-inflammatory, anti-allergic, immune modulation |

Clinical Development Status

Current Phase

Cepharanthine (千金藤素) — Investigational Therapy for Parkinson's Disease

Overview

Cepharanthine (also known as 千金藤素) is a natural bisbenzylisoquinoline alkaloid extracted from the plant Stephania cepharantha Hayata, used traditionally in Chinese medicine for over 70 years. It is being investigated as a potential disease-modifying treatment for Parkinson's disease (PD) due to its multi-target neuroprotective properties that address multiple pathogenic pathways simultaneously["@cepharanthine2015"][@cepharanthine2020].

Compound Information

| Property | Value |
|----------|-------|
| Chemical Name | (1R,2S,3R,4S,6R,7S,8R,13R,14R,15S,16S)-1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17-Octadecahydro-1,6-epoxy-4,15-dihydroxy-5,11-dimethyl-8-(1-methylethenyl)-7,13-epoxy-15H-cyclopenta[a]azulene-3-carboxylic acid |
| Molecular Formula | C₃₇H₃₈N₂O₆ |
| Molecular Weight | 606.7 g/mol |
| Class | Bisbenzylisoquinoline alkaloid |
| Source | Stephania cepharantha (Japanese: Kikyo, Chinese: Jin Qian Teng) |
| Traditional Uses | Anti-inflammatory, anti-allergic, immune modulation |

Clinical Development Status

Current Phase

• Phase: Preclinical / Early clinical (IND-enabling studies)
• Status: Active investigation, multiple research groups
• Indication: Parkinson's disease (early to mid-stage)
• Goal: Disease modification, not just symptomatic relief

Research Pipeline

Mechanism of Action

Cepharanthine exerts neuroprotective effects through multiple interconnected pathways[@cepharanthine2020]. This multi-target approach is particularly attractive for PD, where multiple pathogenic mechanisms contribute to dopaminergic neuron loss.

Anti-inflammatory Effects

The neuroinflammatory response in PD involves activation of microglia in the substantia nigra pars compacta (SNpc), releasing pro-inflammatory cytokines that contribute to neuronal death.

NF-κB Inhibition:

• NF-κB is a key transcription factor driving inflammatory gene expression
• Cepharanthine inhibits IKK kinase activity, preventing IκB degradation
• This blocks NF-κB nuclear translocation and DNA binding
• Downstream effects include reduced iNOS, COX-2, and cytokine expression

• TNF-α: Reduced by up to 70% in microglial cultures
• IL-1β: Decreased production and release
• IL-6: Suppressed synthesis
• MCP-1: Reduced monocyte recruitment

• Shifts microglia from M1 (pro-inflammatory) to M2 (protective) phenotype
• Enhances production of anti-inflammatory cytokines (IL-10, TGF-β)
• Reduces NADPH oxidase-derived superoxide production

Antioxidant Activity

Oxidative stress is a hallmark of PD pathogenesis, with increased markers of lipid peroxidation, protein oxidation, and DNA damage in the SN of PD patients.

ROS Scavenging:

• Direct neutralization of hydroxyl radicals (·OH) and superoxide (O₂⁻)
• Preservation of endogenous antioxidant enzymes (SOD, catalase, GPx)
• Metal chelation prevents Fenton reaction-mediated damage

• Cepharanthine activates Nrf2 (Nuclear factor erythroid 2-related factor 2)
• Nrf2 translocates to the nucleus and binds antioxidant response elements (ARE)
• Upregulates expression of:
• Heme oxygenase-1 (HO-1)
• NAD(P)H quinone dehydrogenase 1 (NQO1)
• Glutamate-cysteine ligase (GCL)
• Thioredoxin (Trx)

• NOX2 is the major source of ROS in activated microglia
• Cepharanthine prevents p47phox phosphorylation and assembly
• Reduces superoxide production by up to 60%

Anti-apoptotic Effects

The intrinsic (mitochondrial) apoptotic pathway is activated in PD neurons due to oxidative damage, calcium dysregulation, and alpha-synuclein toxicity.

Caspase Inhibition:

• Direct inhibition of caspase-3 and caspase-9
• Prevention of cytochrome c release from mitochondria
• Blocking of Apaf-1 apoptosome formation

• Increases anti-apoptotic protein Bcl-2 expression
• Decreases pro-apoptotic Bax translocation to mitochondria
• Maintains mitochondrial membrane potential

• Preserves complex I activity in the electron transport chain
• Enhances ATP production
• Reduces mitochondrial permeability transition
• Improves mitochondrial dynamics (fusion/fission balance)

Alpha-synuclein Modulation

Alpha-synuclein aggregation is the central pathogenic event in PD. Cepharanthine interferes with multiple steps in this process[@autophagy_cepharanthine].

Aggregation Inhibition:

• Binds to the NAC (Non-Aβ Component) region of alpha-synuclein
• Prevents nucleation and oligomer formation
• Reduces formation of toxic soluble oligomers
• Evidence from ThT fluorescence and AFM studies

• May promote clearance of existing aggregates
• Disrupts established fibril structures
• Reduces the seeding capacity of aggregates

• Activates autophagy through mTOR-independent pathways
• Enhances clearance of misfolded proteins via chaperone-mediated autophagy
• Increases Beclin-1 expression and LC3 lipidation
• Particularly important for neurons that cannot divide and must clear debris internally

Additional Mechanisms

Calcium Homeostasis:

• Modulates L-type voltage-gated calcium channels
• Reduces calcium influx that triggers excitotoxicity
• Protects against calcium-induced mitochondrial dysfunction

• Preserves dopaminergic neurons in the substantia nigra
• Maintains tyrosine hydroxylase (TH) activity
• Protects against 6-OHDA and MPTP toxicity

• Evidence for CNS bioavailability from animal studies
• P-glycoprotein substrate with moderate brain penetration
• Studies show accumulation in brain parenchyma

Preclinical Evidence

Cellular Models

| Model | Finding | Reference |
|-------|---------|-----------|
| MPTP-treated SH-SY5Y cells | Reduced apoptosis, preserved viability | [@cepharanthine2015] |
| 6-OHDA-treated PC12 cells | Decreased ROS, maintained mitochondrial function | [@cepharanthine2020] |
| Alpha-synuclein overexpressing cells | Reduced aggregation, increased clearance | [@autophagy_cepharanthine] |
| LPS-activated microglia | Suppressed inflammatory cytokine release | [@tcm_neuroprotection] |

Animal Models

MPTP Model:

• Pretreatment with cepharanthine prevented dopaminergic neuron loss
• Reduced striatal dopamine depletion by 40-60%
• Decreased glial activation in substantia nigra
• Improved behavioral performance in cylinder test

• Unilateral lesion model showed protection of the intact side
• Reduced apomorphine-induced rotations
• Preserved TH-positive neurons in SN

• Alpha-synuclein transgenic mice showed reduced aggregates
• Improved motor function in rotarod and pole tests
• Reduced neuroinflammation on Iba-1 staining

Pharmacokinetics

| Parameter | Value (rodents) |
|-----------|-----------------|
| Oral bioavailability | ~25-30% |
| Brain-to-plasma ratio | 0.8-1.2 |
| Half-life | 4-6 hours |
| Cmax (brain) | 2-3 μg/g at 2h post-dose |
| Protein binding | ~85% |

Clinical Considerations

Potential Advantages

Challenges

Safety Profile

From traditional use and preclinical studies:

• Well-tolerated at therapeutic doses
• No significant toxicity in chronic dosing studies
• Side effects (if any): mild GI effects, rare allergic reactions
• Drug interactions: May affect P450 enzymes

Research Landscape

Compounding Approaches

Cepharanthine is part of a broader movement to explore traditional Chinese medicine (TCM) compounds for neurodegeneration:

• Berberine: AMPK activator, autophagy enhancement
• Curcumin: Anti-inflammatory, antioxidant
• Resveratrol: Sirt1 activator, neuroprotection
• L-theanine: GABA modulation, neuroprotection

Similar Natural Compounds in Development

| Compound | Target | Stage |
|----------|--------|-------|
| Curcumin | Multiple | Phase 2 |
| Resveratrol | Sirt1, inflammation | Phase 3 |
| Epigallocatechin-3-gallate | Multiple | Phase 2 |
| Garlic-derived compounds | Antioxidant | Preclinical |

Future Directions

Planned Clinical Development

Biomarker Development

• Alpha-synuclein: CSF and blood sampling for aggregation studies
• NfL: Neurofilament light chain as neurodegeneration marker
• Inflammatory cytokines: TNF-α, IL-6, IL-1β
• Imaging: DaTscan for dopaminergic integrity

Clinical Significance

Positioning in PD Therapeutics

Cepharanthine represents several emerging trends in PD drug development:

Potential Patient Population

• Early PD: Greatest potential for disease modification
• Patients with rapid progression: Those who may benefit most from neuroprotection
• Those with inflammatory markers: Identifying likely responders
• Treatment-naive: Before significant neuronal loss

Related Pages

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alpha-synuclein](/proteins/alpha-synuclein)
• [Alpha-synuclein Aggregation](/mechanisms/alpha-synuclein-aggregation)
• [Traditional Chinese Medicine](/therapeutics/traditional-chinese-medicine-neurodegeneration)
• [Neuroinflammation in PD](/mechanisms/neuroinflammation-parkinsons)
• [MPTP Model](/mechanisms/mptp-parkinsons-model)
• [Dopaminergic Neurons](/cell-types/dopaminergic-neurons)
• [Oxidative Stress in PD](/mechanisms/oxidative-stress-parkinsons)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Lewy Body Dementia](/diseases/lewy-body-dementia)
• [Multiple System Atrophy](/diseases/multiple-system-atrophy)
• [Autophagy in Neurodegeneration](/mechanisms/autophagy-neurodegeneration)
• [Natural Products in CNS Drug Discovery](/therapeutics/natural-products-cns-drug-discovery)

External Links

• [PubMed - Cepharanthine PD Models](https://pubmed.ncbi.nlm.nih.gov/26249541/)
• [Traditional Chinese Medicine Database](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
• [Parkinson's Foundation](https://www.parkinson.org/)

References